Nkarta, Inc.(NKTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NKTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Nkarta, Inc. (NKTX), a Healthcare sector company. NKTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Nkarta, Inc. reports net income of $-40.4M, free cash flow of $-24.4M. Top institutional holders of NKTX by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock, NEA Management Company, based on the most recent SEC filings. NKTX trades on the Nasdaq exchange and files with the SEC under CIK 1787400. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nkarta, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-40.4M
Free Cash Flow
Q2 2026
$-24.4M
ROIC
Q2 2026
-69.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+4.3% YoYOperating Income
+4.8% YoYEPS (Diluted)
+11.9% YoYTotal Assets
-19.4% YoYOp. Cash Flow
+11.0% YoYFree Cash Flow
+13.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | $0.00 | — |
| Net Income | $-104.1M +4.3% | $-108.8M +7.4% | $-117.5M -3.2% | $-113.8M -32.3% | $-86.1M +5.8% | $-91.4M |
| Operating Income | $-122.0M +4.8% | $-128.2M +2.6% | $-131.7M -10.7% | $-119.0M -37.6% | $-86.4M -67.8% | $-51.5M |
| EPS (Diluted) | $-1.41 +11.9% | $-1.60 +33.3% | $-2.40 +8.0% | $-2.61 +0.4% | $-2.62 | — |
| Total Assets | $404.2M -19.4% | $501.2M +32.3% | $378.9M -19.9% | $472.9M +72.7% | $273.9M -18.9% | $337.6M |
| Operating Cash Flow | $-88.7M +11.0% | $-99.7M -15.7% | $-86.2M -51.2% | $-57.0M +16.1% | $-67.9M -56.1% | $-43.5M |
| Free Cash Flow | $-89.9M +13.6% | $-104.1M +8.9% | $-114.3M -9.8% | $-104.1M -42.7% | $-73.0M -43.0% | $-51.0M |
Get alerted when NKTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nkarta, Inc. including:
Top Institutional Holders of NKTX
RA CAPITAL MANAGEMENT, L.P.
$30.6M10,805,129 shBlackRock, Inc.
$17.8M6,300,212 shNEA Management Company, LLC
$10.1M3,568,781 shSamsara BioCapital, LLC
$9.9M3,507,666 shSR ONE CAPITAL MANAGEMENT, LP
$9.4M3,333,333 shGSK plc
$8.9M3,150,732 shMonaco Asset Management SAM
$6.7M2,373,400 shVANGUARD CAPITAL MANAGEMENT LLC
$6.3M2,226,415 shCITADEL ADVISORS LLC
$6.2M2,174,745 shTWO SIGMA INVESTMENTS, LP
$5.3M1,873,293 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $30.6M | 10,805,129 |
| BlackRock, Inc. | $17.8M | 6,300,212 |
| NEA Management Company, LLC | $10.1M | 3,568,781 |
| Samsara BioCapital, LLC | $9.9M | 3,507,666 |
| SR ONE CAPITAL MANAGEMENT, LP | $9.4M | 3,333,333 |
| GSK plc | $8.9M | 3,150,732 |
| Monaco Asset Management SAM | $6.7M | 2,373,400 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.3M | 2,226,415 |
| CITADEL ADVISORS LLC | $6.2M | 2,174,745 |
| TWO SIGMA INVESTMENTS, LP | $5.3M | 1,873,293 |
More Healthcare Companies
View all Healthcare →Put NKTX on your watchlist
Track score changes the day Nkarta, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NKTX a good stock to buy?
13F Pro's AI-powered analysis of Nkarta, Inc. (NKTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NKTX are available on the NKTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NKTX is classified as a small company.
Which hedge funds own NKTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NKTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nkarta, Inc.'s investment landscape.